Originally published by our sister publication Infectious Disease Special Edition
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 7-4 in favor of the Pfizer respiratory syncytial virus (RSV) bivalent vaccine candidate, PF-06928316 or RSVpreF, in preventing acute respiratory disease and lower respiratory tract disease (LRTD) caused by RSV in adults who are 60 years of age and older. There was one abstention.
There were two votes of 7-4, one for safety and